Novartis' Zortress obtained FDA approval for use in the prevention of liver rejection among patients who receive the transplanted organs. The drug is already approved for kidney transplant patients.
FDA widens OK of Novartis transplant drug
SmartBrief Job Listings for Health Care
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||